Table 1.
Baseline clinical variables of the study population.
| Demographic variables | Control (n, 86) | Tocilizumab (n, 62) | p Value |
|---|---|---|---|
| Male/female (n) | 72/14 (n) | 51/11 (n) | 0.815 |
| Age (years) | 52.8 ± 12.9 | 57.4 ± 14.3 | 0.043 |
| BMI (mean ± SD) | 29.7 ± 6.5 | 29.7 ± 5.7 | 0.970 |
| Comorbidities | |||
| Diabetes mellitus (yes) | 50 (58.1%) | 30 (48.4%) | 0.240 |
| Hypertension (yes) | 26 (30.2%) | 29 (46.8%) | 0.040 |
| Cardiac problem (yes) | 11 (12.8%) | 6 (9.7%) | 0.558 |
| Bronchial asthma (yes) | 11 (12.8%) | 7 (11.3%) | 0.783 |
| Chronic kidney disease (yes) | 1 (1.2%) | 9 (14.5%) | 0.002 |
| CLD (yes) | 0 | 3 (4.8%) | 0.070 |
| CTD (yes) | 0 | 1 (1.6%) | 0.416 |
| Stroke (yes) | 1 (1.2%) | 3 (4.8%) | 0.195 |
| DLP (yes) | 22 (25.6%) | 14 (22.6%) | 0.472 |
| Immunosuppressant (yes) | 1 (1.2%) | 4 (6.5%) | 0.029 |
| Charlson score | 1.00 ± 0.34 | 1.18 ± 0.42 | 0.002 |
| Symptoms | |||
| Fever (yes) | 64 (74.4%) | 55 (88.7%) | 0.031 |
| Cough (yes) | 56 (65.5%) | 50 (80.6%) | 0.039 |
| Sputum (yes) | 41 (47.7%) | 6 (9.7%) | 0.0001 |
| Sore throat (yes) | 3 (3.5%) | 13 (21.0%) | 0.001 |
| Chest pain (yes) | 35 (40.7%) | 4 (6.5%) | 0.0001 |
| Myalgia (yes) | 58 (67.4%) | 10 (16.1%) | 0.0001 |
| Arthralgia (yes) | 11 (12.8%) | 5 (8.1%) | 0.361 |
| Fatigue (yes) | 4 (4.7%) | 28 (45.2%) | 0.0001 |
| SOB (yes) | 70 (81.4%) | 47 (75.8%) | 0.410 |
| Headache (yes) | 3 (3.5%) | 9 (14.5%) | 0.015 |
| Confusion (yes) | 2 (2.3%) | 0 | 0.336 |
| NV | 2 (2.3%) | 13 (21.0%) | 0.0001 |
| Diarrhea/abdominal pain (yes) | 14 (16.3%) | 8 (12.9%) | 0.569 |
| Systolic blood pressure | 122.3 ± 21 | 129.9 ± 16 | 0.052 |
| Duration of symptoms | 4.99 ± 2.37 | 6.39 ± 3.11 | 0.005 |
| Days from admission till TCZ | 2.71 ± 1,42 |